Absolute Versus Relative Bioavailability Estimands

Two Questions, Two References

A formulation can produce more systemic exposure than another oral formulation and still deliver only a small fraction of the exposure associated with intravenous administration. There is no contradiction: the two statements answer different questions. Relative bioavailability compares one formulation with a specified alternative; absolute bioavailability compares an extravascular formulation with intravenous administration.

The reference is therefore part of the meaning of each estimate. A statement such as “bioavailability is 150%” is incomplete unless it says whether the comparison is relative to another formulation or absolute relative to an intravenous reference. These estimates describe dose-normalized exposure under specified conditions; neither, by itself, establishes a clinical benefit or bioequivalence.

Definition: Absolute bioavailability, \(F_{\text{abs}}\), is the dose-normalized AUC after an extravascular dose divided by the dose-normalized AUC after an intravenous dose. Relative bioavailability, \(F_{\text{rel}}\), is the dose-normalized AUC after a test formulation divided by the dose-normalized AUC after a reference formulation. Each estimate is meaningful only with its reference stated.

Why a Relative Advantage Can Coexist With Low Absolute Availability

For a drug with linear pharmacokinetics and systemic clearance \(CL\), dose-normalized AUC after an extravascular dose is proportional to the fraction of the dose reaching systemic circulation, \(F\). For intravenous administration, that fraction is defined as 1. These relationships give the usual estimates:

F_{\text{abs}}= \frac{\mathrm{AUC}_{\text{extravascular}}/D_{\text{extravascular}}} {\mathrm{AUC}_{\text{IV}}/D_{\text{IV}}} \qquad F_{\text{rel}}= \frac{\mathrm{AUC}_{\text{test}}/D_{\text{test}}} {\mathrm{AUC}_{\text{reference}}/D_{\text{reference}}}

Here, \(D\) is the administered dose and AUC is the area under the concentration-time curve for the same active moiety. Dose normalization is important when the doses differ: comparing raw AUCs alone can give the wrong impression about exposure per unit dose.

The connection between the estimates follows directly when both oral formulations are evaluated under comparable conditions. If their fractions reaching systemic circulation are \(F_{\text{test}}\) and \(F_{\text{reference}}\), then their dose-normalized AUCs are \(F_{\text{test}}/CL\) and \(F_{\text{reference}}/CL\). Dividing the first by the second cancels the common clearance:

F_{\text{rel}} = \frac{F_{\text{test}}/CL}{F_{\text{reference}}/CL} = \frac{F_{\text{test}}}{F_{\text{reference}}}

This explains the key interpretive point. If the reference formulation has low absolute availability, a test formulation can have a large relative ratio while its own absolute availability remains low. A relative ratio of 1.5 means 50% greater dose-normalized exposure than that particular reference; it does not mean that 150% of the dose reached systemic circulation.

Assumptions for this interpretation: The compared doses are in a range where exposure is dose-proportional; clearance is comparable across treatments; AUC is measured for the same active moiety over a suitable interval; and treatment conditions do not introduce a systematic difference in disposition. A paired comparison in the same participants can help control between-person differences, but it does not remove the need for these assumptions.

Worked Comparisons

Worked Example: A Relative Advantage With Low Absolute Bioavailability

In a hypothetical study, the same participants receive an intravenous dose, an oral reference formulation, and an oral test formulation. Assume linear pharmacokinetics, comparable clearance across periods, and adequately measured AUCs. The intravenous dose is 100 mg with AUC 100 mg·h/L. The reference oral dose is 100 mg with AUC 8 mg·h/L. The test oral dose is 50 mg with AUC 6 mg·h/L. Calculate the absolute availability of the test and its relative availability versus the reference.

First calculate the dose-normalized AUCs. For intravenous dosing, this is \(100/100=1.00\) mg·h/L per mg. For the oral reference, it is \(8/100=0.0800\) mg·h/L per mg. For the test, it is \(6/50=0.120\) mg·h/L per mg.

The test’s absolute bioavailability is:

F_{\text{abs,test}} = \frac{6/50}{100/100} = \frac{0.120}{1.00} = 0.120 = 12.0\%

Its relative bioavailability versus the oral reference is:

F_{\text{rel,test/reference}} = \frac{6/50}{8/100} = \frac{0.120}{0.0800} = 1.50 = 150\%

Thus, the test has 50% greater dose-normalized exposure than this oral reference, while its absolute estimate is 12.0% relative to intravenous dosing. “High relative, low absolute” is a fair descriptive contrast here, but there is no universal cutoff that makes a relative estimate high or an absolute estimate low. Each number must be interpreted in its own reference frame.

Worked Example: Changing the Reference Changes the Relative Conclusion

Consider a second hypothetical comparison with dose-normalized AUCs of 0.120 mg·h/L per mg for a test formulation, 0.0800 for oral reference A, and 0.200 for oral reference B. Assume the same active moiety, linear pharmacokinetics, and comparable clearance. The test’s absolute bioavailability is independently estimated as 12.0% using an intravenous reference. What relative conclusions follow?

Versus reference A:

F_{\text{rel,test/A}} = \frac{0.120}{0.0800} = 1.50 = 150\%

Versus reference B:

F_{\text{rel,test/B}} = \frac{0.120}{0.200} = 0.600 = 60.0\%

The test provides 50% greater dose-normalized exposure than reference A but 40% less than reference B. Both statements can be correct because the comparator differs. The 12.0% absolute estimate has a different reference—intravenous dosing—and does not change when the oral comparator changes.

Worked Example: Choosing the Estimate That Answers the Question

A hypothetical development team has a candidate oral formulation and an established oral formulation. In a controlled comparison, their dose-normalized AUCs are 0.0900 and 0.0600 mg·h/L per mg, respectively. In a separate, appropriately matched intravenous comparison, the candidate’s dose-normalized AUC is 0.750 mg·h/L per mg. Assume dose proportionality and comparable clearance within each comparison. Which conclusions do these data support?

The relative estimate answers how the candidate compares with the established oral formulation:

F_{\text{rel,candidate/established}} = \frac{0.0900}{0.0600} = 1.50 = 150\%

The absolute estimate uses the intravenous value as its reference:

F_{\text{abs,candidate}} = \frac{0.0900}{0.750} = 0.120 = 12.0\%

The candidate therefore has 50% greater dose-normalized exposure than the established oral formulation, and its absolute estimate is 12.0% relative to intravenous dosing. The first result supports a formulation-to-formulation comparison; the second supports an oral-to-intravenous comparison. Neither calculation alone shows that the candidate improves an outcome, nor does a ratio of 1.50 establish bioequivalence.

Reading the Result and Checking the Comparison

Before interpreting either estimate, state the question and name the reference. “Is the test more available than formulation A?” calls for a relative comparison with A. “What proportion of the intravenous-reference exposure is observed after the oral dose, after accounting for dose?” calls for an absolute comparison. If the available data contain only two oral formulations, they can support a relative estimate but not an absolute estimate without suitable intravenous data.

Several checks help prevent a numerically correct ratio from being interpreted incorrectly:

Check the doses. Use AUC divided by dose for both treatments. Keep dose units consistent, and do not interpret a raw-AUC ratio as a dose-normalized ratio when doses differ.
Check the reference route or formulation. An oral comparator supports a relative conclusion. An intravenous comparator is needed for the usual absolute estimate.
Check comparability. Differences in participants, treatment conditions, or clearance can affect dose-normalized AUC. A ratio across separate settings may reflect those differences as well as formulation differences.
Check the pharmacokinetic assumptions. If exposure is not dose-proportional or clearance changes between treatments, the simple interpretation as a ratio of fractions reaching systemic circulation may not hold.
Check what the endpoint does not say. AUC-based availability does not, by itself, establish equivalence in peak concentration, timing of exposure, safety, or clinical effect.

A common mistake is to see \(F_{\text{rel}}=150\%\) and conclude that 150% of the administered dose reached the circulation. That treats the oral reference as if it were intravenous. The correction is to preserve the denominator in the interpretation: 150% means 1.5 times the reference formulation’s dose-normalized AUC. Only an intravenous-referenced calculation estimates absolute bioavailability under the stated assumptions.

What Each Approach Can and Cannot Establish

Relative and absolute estimates are complementary rather than competing methods. Relative bioavailability is useful for comparing formulations when the practical question concerns one formulation versus another. It requires a suitable formulation reference, but not necessarily intravenous dosing. Absolute bioavailability directly compares extravascular exposure with intravenous exposure; obtaining it therefore requires appropriate intravenous reference data and a comparable pharmacokinetic setting.

The estimates also have different limitations. A relative estimate depends on the chosen comparator, so changing the reference can reverse the direction or alter the size of the conclusion. An absolute estimate depends on the quality and comparability of the intravenous data. Both rely on dose normalization and assumptions about exposure and disposition. In either case, report the estimate together with its reference, doses, and units, and avoid turning an exposure ratio into a broader clinical claim.

The central interpretation is simple: relative bioavailability is a comparison with a named formulation; absolute bioavailability is a comparison with intravenous dosing. A formulation may compare favorably with a weak oral reference while still having low absolute availability. Naming the reference makes that result clear rather than paradoxical.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions.

A test and oral reference have dose-normalized AUCs of 0.150 and 0.100 mg·h/L per mg. What is the test’s relative bioavailability, and what does the percentage mean?
A test’s dose-normalized AUC is 0.0600 mg·h/L per mg, and the intravenous value is 0.600. Calculate its absolute bioavailability.
A formulation has a relative estimate of 200% versus one oral reference. Does that establish that its absolute bioavailability is 200%? Explain.
Why is dose normalization necessary when comparing a 50 mg test dose with a 100 mg reference dose?

Solutions. (1) \(0.150/0.100=1.50=150\%\). The test has 50% greater dose-normalized AUC than that named oral reference; this is not an absolute estimate. (2) \(0.0600/0.600=0.100=10.0\%\), relative to intravenous dosing under the required assumptions. (3) No. It means twice the reference formulation’s dose-normalized AUC; absolute bioavailability requires an intravenous reference. (4) Raw AUC depends on the administered dose, so dividing each AUC by its dose compares exposure per unit dose rather than confounding formulation with dose.